Last update 29 Jun 2024

Lorazepam

Last update 29 Jun 2024

Overview

R&D Status

Clinical Result

Translational Medicine

Overview

Basic Info

SummaryLorazepam, a minute molecular compound, acts as an agonist that targets the GABAA receptor. It boasts a varied scope of medical uses, such as assuaging anxiety disorders, depressive disorder, epilepsy, sleep initiation and maintenance disorders, and even catatonia in Down Syndrome patients. Initially greenlighted by Bausch Health in 1970, this drug ushers in a binding process, whereby the GABAA receptor in the central nervous system is targeted, and subsequently leads to heightened GABAergic inhibitory neurotransmission, which deftly quashes neuronal activity and thus facilitates sedative, anxiolytic, and anticonvulsant effects. Despite the benefits of this medication, it is prudent to bear in mind the potential for adverse effects, which may include drowsiness, dizziness, and impaired coordination. With prolonged usage, there is a possibility of developing dependence on the drug, hence why it is indispensable to utilize Lorazepam only under the watchful eye of a competent healthcare provider.

Drug Type

Small molecule drug

Synonyms

Lora-Pita Intravenous, Lorazepam (JP17/USP/INN), o-Chlorooxazepam

+ [16]

Target

GABAA receptor

Mechanism

GABAA receptor agonists(Gamma-aminobutyric acid A receptor agonists)

Therapeutic Areas

Nervous System DiseasesOther DiseasesCongenital Disorders

Active Indication

Sleep Initiation and Maintenance DisordersSedationStatus Epilepticus+ [5]

Inactive Indication

Generalized anxiety disorder

Originator Organization

Bausch Health Cos., Inc.

Active Organization

Bausch Health US LLCHikma Pharmaceuticals USA, Inc.

Almatica Pharma LLC

+ [4]

Inactive Organization

Pfizer Inc.

Edgemont Pharmaceuticals LLC

Drug Highest PhaseApproved

First Approval Date

US (30 Sep 1977),

Anxiety DisordersAnxietyDepressive Disorder

Regulation-

Structure

Molecular FormulaC15H10Cl2N2O2

InChIKeyDIWRORZWFLOCLC-UHFFFAOYSA-N

CAS Registry846-49-1

120

Clinical Trials associated with Lorazepam

NCT05964647 / RecruitingPhase 1IIT

Effect of Ketanserin, Olanzapine, and Lorazepam After LSD Administration on the Acute Response to LSD in Healthy Subjects

The main objective of this study is to determine whether administration of ketanserin (40 mg), olanzapine (10 mg), and lorazepam (2 mg) after administration of LSD (150 µg) attenuates and shortens the subjective LSD response (any drug effect) compared to administration of LSD (150 µg) alone

Start Date01 Feb 2024

Sponsor / Collaborator

Universitätsspital Basel

ISRCTN49118865 / CompletedPhase 1

Comparative bioavailability study of a new IBSA Lorazepam 2.5 mg orodispersible film and Tavor® (lorazepam) 2.5 mg film-coated tablets in healthy volunteers under fasting conditions

Start Date29 Jan 2024

Sponsor / Collaborator

IBSA Institut Biochimique SA

NCT06004115 / RecruitingPhase 4IIT

Processes and Circuitry Underlying Threat Sensitivity as a Treatment Target for Co-morbid Anxiety and Depression

This mechanistic study uses an anti anxiety drug and brain imaging to study the threat processing system and associated brain circuits in people with depression, anxiety disorders and comorbid depression and anxiety disorders. In a double blind, placebo controlled crossover design, up to 65 individuals will be recruited who will have a diagnosis of major depressive disorder (MDD) and at least one anxiety disorder (AD) (AD-MDD group), up to 65 participants will have a diagnosis of MDD and no diagnosis of an AD and up to 65 participants will have no diagnosis of MDD and a diagnosis of at least one AD will be enrolled to participate in an two session study to obtain 150 completers (50 per group). All participants will receive a single dose of Lorazepam and placebo (order randomized) taken orally. After the
2.5 hr screening session, participants will complete two identical
5 hr experimental sessions, each of which include a 30 min eyeblink startle session and a 1 hr functional magnetic resonance imaging (MRI) brain scan session. The total time involved in the study is approximately 10.5 hours.
The main questions the study seeks to answer are:
are people with comorbid depression and anxiety different than those with depression alone in terms of their eyeblink startle response to threat?
are people with comorbid depression and anxiety different than those with depression alone in terms of their brain activation in response to threat?
are people with comorbid depression and anxiety different than those with depression alone in terms of their responses to anxiety drugs?

Start Date08 Nov 2023

Sponsor / Collaborator

Laureate Institute for Brain Research

[+2]

100 Clinical Results associated with Lorazepam

100 Translational Medicine associated with Lorazepam

100 Patents (Medical) associated with Lorazepam

4,338

Literatures (Medical) associated with Lorazepam

01 May 2024·Current drug safety

Amoxicillin Induced Fever, Rash, and Catatonia - A Case Study

Author: Ranka, Rajat ; Panda, Prasan Kumar ; Yadav, Chunnu Kumar ; Krishnan, Vijay ; Shah, Bishal Pratap ; Mishra, Mayank Kumar

Introduction::

Adverse drug reactions (ADR) are defined as any harmful or unpleasant events or injuries resulting from the use of any particular drug. Among those antibiotics that cause adverse reactions, amoxicillin is one of them. Catatonia and vasculitic rash are its rare adverse effects.

Case Presentation::

A 23-year-old postpartum female, with a history of taking empirical Amoxiclav (amoxicillin-clavulanic acid 625 mg) injection and oral tablets for episiotomy wound, presented with altered sensorium and fever followed by maculopapular rash. On examination, she had generalized rigidity with waxy flexibility that improved by lorazepam challenge and was diagnosed as catatonia. On evaluation, amoxicillin was found to be precipitating catatonia in this patient.

Conclusion::

Since the diagnosis of catatonia is often missed, any cases with clinical presentation of fever, rash, altered sensorium, and generalized rigidity should also be suspected for druginduced ADR and the precipitating factor should be searched for.

01 Mar 2024·The Science of the total environment

A thorough analysis of the occurrence, removal and environmental risks of organic micropollutants in a full-scale hybrid membrane bioreactor fed by hospital wastewater

Article

Author: Avolio, Francesco ; Repec, Siniša ; Zanella, Marcello ; Gutierrez, Marina ; Stipaničev, Draženka ; Mutavdžić Pavlović, Dragana ; Verlicchi, Paola

The Urban Wastewater Treatment Directive recent draft issued last October 2022 pays attention to contaminants of emerging concern including organic micropollutants (OMPs) and requires the removal of some of them at large urban wastewater treatment plants (WWTPs) calling for their upgrading. Many investigations to date have reported the occurrence of a vast group of OMPs in the influent and many technologies have been tested for their removal at a lab- or pilot-scale. Moreover, it is well-known that hospital wastewater (HWW) contains specific OMPs at high concentration and therefore its management and treatment deserves attention. In this study, a 1-year investigation was carried out at a full-scale membrane bioreactor (MBR) treating mainly HWW. To promote the removal of OMPs, powdered activated carbon (PAC) was added to the bioreactor at 0.1 g/L and 0.2 g/L which resulted in the MBR operating as a hybrid MBR. Its performance was tested for 232 target and 90 non-target OMPs, analyzed by UHPLC-QTOF-MS using a direct injection method. A new methodology was defined to select the key compounds in order to evaluate the performance of the treatments. It was based on their frequency, occurrence, persistence to removal, bioaccumulation and toxicity. Finally, an environmental risk assessment of the OMP residues was conducted by means of the risk quotient approach. The results indicate that PAC addition increased the removal of most of the key OMPs (e.g., sulfamethoxazole, diclofenac, lidocaine) and OMP classes (e.g., antibiotics, psychiatric drugs and stimulants) with the highest loads in the WWTP influent. The hybrid MBR also reduced the risk in the receiving water as the PAC dosage increased mainly for spiramycin, lorazepam, oleandomycin. Finally, uncertainties and issues related to the investigation being carried out at full-scale under real conditions are discussed.

01 Feb 2024·The Canadian veterinary journal = La revue veterinaire canadienne

Separation and confinement anxiety in a golden retriever × standard poodle dog.

Author: Heinrich, Anneliese ; Calder, Christine

An 8-month-old spayed female golden retriever × standard poodle dog was presented for assessment because of vocalization, destructive behavior, and urination when left home alone and confined in a crate. Previous treatments included multiple medications, graduated departures, decoupling of departure cues, and punishmentbased techniques. Adverse reactions to paroxetine and lorazepam were noted before successful treatment with clomipramine, "safe haven" training, and behavior modification. Key clinical message: Separation anxiety is a common behavioral disorder in dogs. It is often treatable but may require changes in the approach to both medication and behavior modification based on patient and client factors.

News (Medical) associated with Lorazepam

26 Jun 2024

·www.biospace.com

Crossject elaborates on ZEPIZURE® potential in light of landmark RAMPART study and its own, recently published, bioequivalence study

Landmark RAMPART study established midazolam intramuscular (IM) injection as a standard of care in the pre-hospital emergency management of epilepsy crises compared to traditional benzodiazepine intravenous (IV) Crossject’s bioequivalence study, recently published in Neurology and Therapy, remarkably consistent with RAMPART’s findings and authors’ views Dijon, France 26 June, 2024 -- Crossject (ISIN: FR0011716265; Euronext: ALCJ), a specialty pharma company in advanced phases of development and registration for ZEPIZURE®, its emergency treatment for the management of epileptic crises based on its award-winning needle-free auto-injector ZENEO®, provides additional, clinically meaningful perspectives on ZEPIZURE® in light of its recently published bioequivalence study results and of the conclusions and hints by the authors of the RAMPART (Rapid Anticonvulsant Medication Prior to ARrival Trial) study1, a landmark double-blind randomized clinical trial comparing the efficacy of IM midazolam vs. IV lorazepam in the pre-hospital treatment of status epilepticus by paramedics. Status epilepticus is defined as a seizure lasting more than 5 minutes. RAMPART unequivocally raised IM midazolam to the status of standard-of-care in the pre-hospital emergency management of status epilepticus by demonstrating its non-inferiority vs. IV lorazepam, as its primary endpoint. Moreover, IM midazolam demonstrated statistically significant superiority (p value<0.001) on the percentage of patients arriving in hospital seizure-free, which was 10% higher when using IM midazolam (329 out of 448 patients or 73.4% vs. 63.4% in the IV lorazepam 445-patient arm). These results underscored the importance of the speed of IM administration of midazolam, as an easy to store and pre-prepared medication for use by paramedics, features that were likely critical in driving efficacy in controlling seizures by the time of arrival in emergency departments. RAMPART was one of the largest studies every conducted in emergency settings, involving 4,314 paramedics, 33 EMS (Emergency Medical Services) units and 79 hospital ER (Emergency Room) departments across the U.S. It was supported by the National Institute of Health (NIH) and by the Biomedical Advanced Research and Development Authority (BARDA). The RAMPART study publication can be found here. Crossject’s study, recently published in the peer-reviewed journal Neurology and Therapy, positively echoed the benefits implied from RAMPART and is remarkably consistent with certain hints put forward by the authors in the RAMPART study. In Crossject’s study, ZEPIZURE® was equivalent to the IM injection from a syringe equipped with a 30mm needle (Dormicum®), and results also suggested a 2-fold lower variability as compared to that usually observed for routes of administration such as intranasal. With some vision and based on their experience then, RAMPART authors had highlighted a number of issues regarding intranasal solutions in epileptic seizures in general, and their prediction of the likely dominance of the IM route for the future. Today, no intranasal solution is approved for the management of status epilepticus. According to RAMPART’s authors, the upfront minutes were critical factors in driving the 10% superiority of IM midazolam, administered through traditional manual vial-form injectable, in positive clinical outcome by ER arrival. ZEPIZURE®, as an ultra-rapid two-step injection, strongly resonates in this practical interventional reality and is likely to further improve the speed of action by healthcare professionals and reliability in injecting a full dose of midazolam. Furthermore, in Crossject’s study, ZEPIZURE® enhanced the midazolam absorption during the very first few minutes post-injection, possibly resulting from the needle-free 50 milliseconds injection compared to manual IM and suggesting that seizure treatment may be efficient even sooner. Patrick Alexandre, CEO of Crossject added: “Beyond the 505(b)(2) regulatory and market gate for ZEPIZURE® into the arsenal available to healthcare professionals in status epilepticus episodes, as potentially the most rapid-to-use and lowest variability tool for the delivery of a complete midazolam dose pre-hospital, our product presents additional upside. ZEPIZURE®’s rapid and easy two-step application should potentially require limited training compared to traditional injectables, and its consistency in administering an effective dose would confer a key advantage. ZEPIZURE® is therefore poised to provide all patients, and their relatives or caregivers, with the professional standard-of-pre-hospital-care solution anytime and anywhere. Our team in Europe and the U.S. is now executing our development strategy to materialize these broad prospects, aiming to position ZEPIZURE® from a productivity contribution to healthcare professionals toward a high impact solution for all patients and families at risk of a broad range of epilepsy seizures.” About Crossject Crossject SA (Euronext: ALCJ; ) is an emerging specialty pharmaceuticals company developing medicines for emergency situations harnessing its award-winning needle-free auto-injector ZENEO® platform. Crossject is in advanced regulatory development for ZEPIZURE®, an epileptic rescue therapy, for which it has a $60 million contract* with the U.S. Biomedical Advanced Research and Development Authority (BARDA). The Company’s versatile ZENEO® platform is designed to enable patients or untrained caregivers to easily and instantly deliver a broad range of emergency medicines via intramuscular injection on bare skin or even through clothing. The Company’s other products in development include mainly solutions for allergic shocks and adrenal insufficiencies, as well as therapies and other emergency indications. * Contract no: 75A50122C00031 with the Department of Health and Human Services; Administration for Strategic Preparedness and Response; Biomedical Research and Development Authority For further information, please contact: Investors Natasha Drapeau Cohesion Bureau +41 76 823 75 27 natasha.drapeau@cohesionbureau.com Media Sophie Baumont Cohesion Bureau +33 6 27 74 74 49 sophie.baumont@cohesionbureau.com 1Silbergleit et al. New England Journal of Medicine, February 2012. Clinicaltrials.gov NCT05026567 Attachment PR RAMDORM 25 June 2024_v9

Clinical ResultClinical Study

07 Mar 2024

·www.prnewswire.com

Gabather reports initial positive results from the EEG/fMRI target engagement study

STOCKHOLM, March 7, 2024 /PRNewswire/ -- Gabather AB (Nasdaq First North Growth Market: GABA) today reports initial positive results from the EEG/fMRI target engagement study, a double-blinded placebo-controlled, cross-over phase Ib study of Gabather's GABAA-receptor positive allosteric modulator, GT-002, in healthy volunteers. The study met the primary objective to confirm a favourable safety and tolerability profile of GT-002. The secondary objective to demonstrate target engagement in human brain was also met. The study clearly demonstrated that GT-002 is safe and well tolerated at dose levels expected to be effective for treatment of patients with neuropsychiatric disorders. Clinically relevant effects of GT-002 were observed on modulation of EEG frequency band power with a significant increase in alpha band power, compared to Lorazepam at the 2-hour after treatment. This effect spanned various brain regions, including frontal and occipital areas. No significant effect of Lorazepam on EEG alpha band power compared to placebo was observed. The results suggest a distinct effect of GT-002 to modulate alpha band power across specific cortical regions. EEG alpha band power is recognized as a marker of cognitive activity such as attention and associated with relaxation and less anxiety, an increase in alpha band may be beneficial for a number of different neuropsychiatric conditions. Of particular clinical interest are the reports that negative symptoms in schizophrenia patients are associated with reduced EEG alpha band power. "We have now proven clinically relevant target engagement in the human brain following oral administration of GT-002 showing that EEG and neuroimaging techniques can indeed open 'a window into the brain' and drive the drug development process of our candidate drugs. The next data to be presented will be a refined analysis of the EEG data during task performance and the fMRI neuroimaging data. With these results at hand, we will move forward into clinical trials in patients and identify the right partner for the continued development of GT-002," says Michael-Robin Witt, CEO of Gabather AB. GT-002 Background GT-002 is a small molecule GABAA receptor Positive Allosteric Modulator (PAM) eliciting both tonic and phasic inhibitory currents. GT-002 improves learning and memory in preclinical models. It restores ketamine induced cognitive deficits in the discrimination learning task model, and inhibits the behavioural effects induced by phencyclidine in the in-vivo model of schizophrenia. GT-002 has been shown to be anxiolytic and to promote social interaction in rats. GT-002 targets a novel binding site on GABAA receptors, different from benzodiazepines (BZD), and has not shown any of the side effects known for BZD. Long-term treatment (28 days) with GT-002 has not shown any withdrawal symptoms upon cessation of treatment both in mice and dogs, indicating no drug abuse liability associated with this drug candidate. GT-002 has successfully completed three phase I clinical trials in healthy volunteers. Both single ascending dose (SAD) and multiple ascending dose (MAD) studies have been completed. The results from these studies show that GT-002 is safe and well tolerated and that it has excellent pharmacokinetic properties, allowing for once-a-day oral dosing. Contact Information Michael-Robin Witt, CEO Phone: 073-687 28 39 E-mail: [email protected] About Gabather Gabather is a clinical-stage pharmaceutical company aiming to transform the treatment of neuropsychiatric disorders. The Company was founded as a response to the significant unmet need and lack of innovative therapeutics in the mental health treatment landscape. Gabather is dedicated to developing innovative therapeutics for the treatment of a broad range of neuropsychiatric disorders. The goal is to accelerate the development of new groundbreaking medicines to achieve clinically meaningful therapies for the patients. For more information, please visit: Certified Adviser Corpura Fondkommission AB Phone: +4672-252 34 51 Email: [email protected] Forward-looking statement This press release contains forward-looking statements that constitute subjective estimates and forecasts about the future. Assessments about the future are only valid on the date they are made and are, by their nature, similar to research and development work in the biotech field, associated with risk and uncertainty. In light of this, actual outcomes may differ substantially from what is described in this press release. Gabather is listed on First North Growth Market and Corpura Fondkommission AB is Certified Advisor. The following files are available for download:

Phase 1Clinical Result

04 Dec 2023

·www.sciencedaily.com

New wearable communication system offers potential to reduce digital health divide

Researchers developed a wearable device that can transmit health data 2,400 times the distance of Wi-Fi without significant network infrastructure. Wearable devices that use sensors to monitor biological signals can play an important role in health care. These devices provide valuable information that allows providers to predict, diagnose and treat a variety of conditions while improving access to care and reducing costs. However, wearables currently require significant infrastructure -- such as satellites or arrays of antennas that use cell signals -- to transmit data, making many of those devices inaccessible to rural and under-resourced communities. A group of University of Arizona researchers has set out to change that with a wearable monitoring device system that can send health data up to 15 miles -- much farther than Wi-Fi or Bluetooth systems can -- without any significant infrastructure. Their device, they hope, will help make digital health access more equitable. The researchers introduced novel engineering concepts that make their system possible in an upcoming paper in the journal Proceedings of the National Academy of Sciences. Philipp Gutruf, an assistant professor of biomedical engineering and Craig M. Berge Faculty Fellow in the College of Engineering, directed the study in the Gutruf Lab. Co-lead authors are Tucker Stuart, a UArizona biomedical engineering doctoral alumnus, and Max Farley, an undergraduate student studying biomedical engineering. Designed for ease, function and future The COVID-19 pandemic, and the strain it placed on the global health care system, brought attention to the need for accurate, fast and robust remote patient monitoring, Gutruf said. Non-invasive wearable devices currently use the internet to connect clinicians to patient data for aggregation and investigation. "These internet-based communication protocols are effective and well-developed, but they require cell coverage or internet connectivity and main-line power sources," said Gutruf, who is also a member of the UArizona BIO5 Institute. "These requirements often leave individuals in remote or resource-constrained environments underserved." In contrast, the system the Gutruf Lab developed uses a low power wide area network, or LPWAN, that offers 2,400 times the distance of Wi-Fi and 533 times that of Bluetooth. The new system uses LoRa, a patented type of LPWAN technology. "The choice of LoRa helped address previous limitations associated with power and electromagnetic constraints," Stuart said. Alongside the implementation of this protocol, the lab developed circuitry and an antenna, which, in usual LoRa-enabled devices, is a large box that seamlessly integrates into the soft wearable. These electromagnetic, electronic and mechanical features enable it to send data to the receiver over a long distance. To make the device almost imperceptible to the wearer, the lab also enables recharge of its batteries over 2 meters of distance. The soft electronics, and the device's ability to harvest power, are the keys to the performance of this first-of-its-kind monitoring system, Gutruf said. The Gutruf Lab calls the soft mesh wearable biosymbiotic, meaning it is custom 3D-printed to fit the user and is so unobtrusive it almost begins to feel like part of their body. The device, worn on the low forearm, stays in place even during exercise, ensuring high-quality data collection, Gutruf said. The user wears the device at all times, and it charges without removal or effort. "Our device allows for continuous operation over weeks due to its wireless power transfer feature for interaction-free recharging -- all realized within a small package that even includes onboard computation of health metrics," Farley said. Gutruf, Farley and Stuart plan to further improve and extend communication distances with the implementation of LoRa wireless area network gateways that could serve hundreds of square miles and hundreds of device users, using only a small number of connection points. The wearable device and its communication system have the potential to aid remote monitoring in underserved rural communities, ensure high-fidelity recording in war zones, and monitor health in bustling cities, said Gutruf, whose long-term goal is to make the technology available to the communities with the most need. "This effort is not just a scientific endeavor," he said. "It's a step toward making digital medicine more accessible, irrespective of geographical and resource constraints."

100 Deals associated with Lorazepam

External Link

KEGG	Wiki	ATC	Drug Bank
D00365	Lorazepam	N05BA06	DB00186

R&D Status

Approved

10 top approved records.

to view more data

Indication	Country/Location	Organization	Date
Sleep Initiation and Maintenance Disorders	CN	Hunan Dongting Pharmaceutical Co., Ltd.	10 Oct 2003
Sedation	US	Hikma Pharmaceuticals USA, Inc.	25 Jul 1980
Status Epilepticus	US	Hikma Pharmaceuticals USA, Inc.	25 Jul 1980
Catatonia	JP	Pfizer Japan, Inc.	04 Nov 1977
Anxiety	US	Bausch Health US LLC	30 Sep 1977
Anxiety Disorders	US	Bausch Health US LLC	30 Sep 1977
Depressive Disorder	US	Bausch Health US LLC	30 Sep 1977

Developing

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Generalized anxiety disorder	Phase 3	US	Edgemont Pharmaceuticals LLC	01 Jan 2015
Down Syndrome	Phase 2	US	The University of Colorado	22 Dec 2022

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT00721526 (CTgov)	Phase 4	Alcoholism \| Anxiety Disorders	41	disulfiram+lorazepam	cyofqxheui(bbjxkicpuh) = veyoklzgbr zdjtxfmllz (qllecowkxd, xnlhovhiqi - ngwpvabraf) View more	-	30 Aug 2023
NCT03435692 (CTgov)	Not Applicable	Analgesia \| Pain, Postoperative	42	ropivacaine (Lumbar Epidural Catheter (< 6 Years Old))	tvrcoxqhuh(bjowalfwrt) = qjoljeqbej xdjnroqeoh (knpmiufmad, tgofsggwng - ysvputhbyn) View more	-	02 Nov 2021
				ropivacaine (Lumbar Plexus Catheter (< 6 Years Old))	tvrcoxqhuh(bjowalfwrt) = hoxvpibxtm xdjnroqeoh (knpmiufmad, nclvzoouvd - ktcsvmknnf) View more
NCT03090620 (CTgov)	Phase 4	Toxicity	19	Physostigmine (Physostigmine)	vyfldekmxa(jfghuufbia) = fszqfjbyjm ezknkvtfgv (lqhpenalwk, kychquckmr - zylsztmfhd) View more	-	23 Aug 2021
				Lorazepam (Lorazepam)	vyfldekmxa(jfghuufbia) = ahguegpafj ezknkvtfgv (lqhpenalwk, yvttwtucox - fvvsxcngwt) View more
NCT01949662 (CTgov)	Phase 2	Delirium \| Advanced cancer	93	Lorazepam+Haloperidol (Intervention Group (Lorazepam & Haloperidol))	otxudauhnu(qfgptadzob) = psmzlegvuw dibltafydm (zdtsuufygs, mvmkiayife - nmgmpthbrz) View more	-	30 Oct 2020
				Placebo+Haloperidol (Control Group (Placebo & Haloperidol))	otxudauhnu(qfgptadzob) = lxchpofleo dibltafydm (zdtsuufygs, ltfpznjhue - mfbvkgudrx) View more
NCT03202550 (CTgov)	Phase 4	Pain	27	Placebo Comparator (Placebo Arm)	hjmmlvuqri(lfcyaqswef) = xvdsrbwpht nzhvktxjkx (xupjdjzhob, zmjnapweyq - smcljpnmwe) View more	-	06 Mar 2020
				Lorazepam+Oxycodone (Active Drug Arm: Lorazepam and Oxycodone)	hjmmlvuqri(lfcyaqswef) = ibwsbkjwwr nzhvktxjkx (xupjdjzhob, qittdlspua - nwiydgbljh) View more
NCT03756038 (CTgov)	Phase 2	Respiratory Distress Syndrome \| Acute Pain	1	Lorazepam (Drug: Oral Lorazepam (1mg))	souxpuyzuu(fcurrdakdu) = mtxdnayzgi oqubhmgrxo (slysaobift, voivsdihyc - ysbcqgikrd) View more	-	26 Feb 2020
				Placebos (Drug: Oral Placebo)	gqoitkwulu(tpwzztzcpz) = ljdkrgafcg nndqrrtxjf (enirrhkjra, maaamlqsai - rmqmhvrxcv) View more
NCT03180632 (Pubmed \| Paediatr Drugs)	Phase 2	-	101	Oral Lorazepam	rogzeqwbah(tuskdepudi) = fxeblusdnk ijxchmgkww (ehqgzbgern ) View more	Positive	01 Oct 2019
				Placebo	rogzeqwbah(tuskdepudi) = jgrvuwwdex ijxchmgkww (ehqgzbgern ) View more
NCT00457366 (CTgov)	Phase 4	Agitation	72	Quetiapine	oszcddfsog(ghohajlupv) = qtfcrurvlt yqpkocwuxb (eujbyjwylr, udlgbcdviu - ynqmrijhwa) View more	-	05 Jul 2019
NCT01330459 (CTgov)	Phase 4	Pain	121	hydrocodone/acetaminophen+Lidocaine+Lorazepam+ibuprofen (Hydrocodone/Acetaminophen)	xpvrvtuhjt(isqpzyklfj) = ezvatkilrb htqteowkbo (olxkpysbge, kerkiliipu - mjlxrytmme) View more	-	26 Apr 2019
				placebo+Lidocaine+Lorazepam+ibuprofen (Placebo)	xpvrvtuhjt(isqpzyklfj) = kokdcahndk htqteowkbo (olxkpysbge, jjlnklqhaj - yzblfaewfq) View more
NCT02239380 (CTgov)	Phase 3	Status Epilepticus	26	Lorazepam	iixxsamhrq(evstmjvjut) = xjrljjiefj oezeolecol (iwvfzbvugm, nmyfgnvuam - dehkmsiukc) View more	-	18 Feb 2019

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Leverages most recent intelligence information, enabling fullest potential.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis